Human Microbiome Market

Global Human Microbiome Market Size (2024 to 2032)

During the forecast period, the global human microbiome market is expected to register a CAGR of 22.42% and be worth USD 6867.60 million by 2032 from USD 1361.38 million in 2024.

MARKET DRIVERS

The growing chronic disease patient population primarily drives the human microbiome market growth.

The patient count suffering from chronic diseases such as inflammatory bowel disease (IBD), diabetes, and obesity is growing rapidly worldwide. These diseases have a close connection with changes in the microbiome. Due to this, the demand for microbiome-based therapies has increased significantly and also led to the development of several microbiome therapies such as probiotics, prebiotics, fecal microbiota transplantation (FMT), and microbial therapeutics. These are believed to be restoring the balance of the microbiome and improving health outcomes.

The rising awareness among people and healthcare professionals regarding the importance of microbiomes in maintaining overall health is driving the demand for microbiome products and services and contributing to human microbiome market growth. Several healthcare organizations have conducted numerous research and developmental activities to understand the role of the microbiome in overall health and developed new microbiome-based therapies and diagnostic tools. This trend is likely to continue in the coming years and contribute to market growth.

In addition, the growing number of investments by the market participants for the development of innovative and effective microbiome products and services, rapid adoption of technological developments in sequencing and analysis to develop innovative microbiome-based products and services and the growing demand for personalized medicine drive the human microbiome market growth. Furthermore, factors include rising awareness among people and healthcare providers regarding the benefits of probiotics and prebiotics such as dietary supplements and functional foods, the favorable regulatory environment of microbiome-based therapies by regulatory bodies and increasing demand for natural and sustainable products fuel the market’s growth rate. Increasing adoption of microbiome-based testing, rising emphasis on preventive healthcare, growing prevalence of antibiotic-resistant infections, rising demand for animal feed additives and rising usage of microbiome-based therapies in clinical trials further accelerate the growth of the human microbiome market.

MARKET RESTRAINTS

A limited understanding of the microbiome is one of the major factors hampering the growth of the human microbiome market. High costs associated with the development and commercialization of microbiome-based products and therapies and limited reimbursement policies further hinder the market’s growth rate.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Human Microbiome Market Analysis By Disease

Based on the disease, the infectious disease segment is predicted to grow at the fastest CAGR during the forecast period in the worldwide human microbiome market owing to the rising prevalence of infectious diseases such as Zika virus, Ebola, and COVID-19. The development of new technologies and tools such as metagenomics and next-generation sequencing to study microbiomes further fuelling segmental growth. Furthermore, the growing awareness among healthcare professionals and patients regarding the importance of the human microbiome is another attribute contributing to segmental growth.

Global Human Microbiome Market Analysis By Product

In 2023, the probiotics segment accounted for the most significant share of the global human microbiome market based on the product and the domination of the segment is likely to continue throughout the forecast period. The segmental growth is primarily driven by the rising awareness about the benefits of probiotics in maintaining gut health, the rising prevalence of digestive disorders, and the growing popularity of functional foods. The growing demand for probiotic supplements and the development of new probiotic strains are further fuelling the growth rate of the segment.

The food segment is estimated to showcase a promising CAGR during the forecast period. Factors such as the rising popularity of functional foods, the increasing demand for natural and healthy food products and the rising prevalence of chronic diseases, such as diabetes and obesity majorly drive the segmental growth.

The medical foods segment is expected to witness a healthy CAGR during the forecast period owing to factors such as the growing patient population suffering from diseases such as Alzheimer's, Parkinson's, and cancer that require specialized nutritional support, increasing demand for personalized nutrition and the growing awareness about the benefits of medical foods.

The diagnostic devices segment is projected to register a notable CAGR during the forecast period owing to factors such as the growing demand for early diagnosis and treatment of diseases, the increasing prevalence of infectious diseases and the rising adoption of molecular diagnostic technologies.

Global Human Microbiome Market Analysis By Application

Based on the application, the therapeutic segment is predicted to control the major share of the global human microbiome market during the forecast period. The growing patient population of chronic diseases such as diabetes, cancer, and inflammatory bowel disease (IBD) and the growing demand for personalized medicine majorly fuels segmental growth. In addition, the development of microbiome-based therapeutics and the increasing investment in microbiome research fuels the segment’s growth rate.

On the other hand, the diagnostics segment is expected to witness a healthy CAGR during the forecast period owing to the rising demand for early diagnosis and treatment of diseases, the growing prevalence of infectious diseases and the growing adoption of molecular diagnostic technologies. The growing investments in microbiome research and the development of new diagnostic technologies are further driving segmental growth.

REGIONAL ANALYSIS

Geographically, the North American market had the largest share of the worldwide market in 2023 and is anticipated to continue its domination throughout the forecast period. The presence of well-established healthcare infrastructure, increasing investment in microbiome research, and the high prevalence of chronic diseases drive regional market growth. In addition, factors such as rising demand for personalized medicine and the increasing awareness about the benefits of microbiome-based products, the presence of key market players and the availability of advanced diagnostic and therapeutic technologies further boost the growth of the North American human microbiome market. The U.S. market held the largest share of the global market in 2023, followed by Canada.

The European human microbiome market was the second largest regional market for human microbiome worldwide in 2023 and is expected to occupy a notable share of the global market during the forecast period. Increasing awareness about the benefits of microbiome-based products, the rising demand for personalized nutrition and medicine, and the growing prevalence of chronic diseases contribute to the European market growth. Factors include the sophisticated healthcare infrastructure, increasing investments in microbiome research, the development of new diagnostic and therapeutic technologies and the presence of key market players accelerating the European market growth. The UK market occupied the largest share of the European market in 2023.

APAC had the third largest share of the worldwide market in 2023 and is expected to be the fastest-growing regional market globally during the forecast period. The growing prevalence of chronic diseases, the rising demand for personalized nutrition and medicine, increasing investments in healthcare infrastructure, the development of new diagnostic and therapeutic technologies, the large patient pool and the presence of key market players drive the growth of the human microbiome market in APAC. China held the major share of the APAC market in 2023 and is expected to witness a healthy CAGR during the forecast period. India and Japan are predicted to showcase a notable CAGR during the forecast period.

Latin America is predicted to witness a healthy CAGR during the forecast period in the worldwide market. The growth of the Latin American market is attributed to the growing adoption of microbiome-based products, the rising prevalence of chronic diseases. Mexico and Brazil accounted for the major share of the Latin American market in 2023.

MEA is estimated to showcase a moderate CAGR during the forecast period.

KEY MARKET PARTICIPANTS

Companies that are playing a noteworthy role in the global human microbiome market profiled in this report are Microbiotica, Rebiotix, Inc., Locus Biosciences, Second Genome Inc., Osel Inc., Second Genome, Kallyope, Finch Therapeutics, Concentric, Synthetic Biologics, Inc., DuPont, BiomX Ltd, MaaT Pharma, Eligo Bioscience, SNIPR Biome, Ritter Pharmaceuticals, DayTwo, Yeda Research and Development Co. Ltd., MyBiome, AOBiome, Enterome, Yakult Honsha Co., Ltd., MicroBiome Therapeutics LLC, and Metabiomics Corporate.

RECENT MARKET DEVELOPMENTS

• In November 2022, the first agency-approved fecal microbiota product, Rebyota, received approval from the United States Food and Drug Administration to prevent Clostridioides difficile, bacteria that can cause CDI in adults, preventing them from a life-threatening condition that causes diarrhea and severe inflammation of the colon.
• In November 2022, to understand the mechanism of microbes interacting with hosts, a new research center has opened on Imperial's Silwood campus by Leverhulme Center for Holobiont with the collaboration of Wellcome Sanger Institute. It aims to characterize varying relationships of multi celled-microbiomes.
• In 2020, 4D Pharma and Longevity Acquisition Corporation became a NASDAQ-listed company. Longevity will, in turn, support and speed up the development of 4D Pharma's Live Biotherapeutic. The FDA defines Living Biotherapeutics as biological products containing a live organism, such as a bacterium, used to prevent, treat, or cure disease.
• In April 2020, Gilead Sciences, Inc. and Second Genome, a leader in microbiome science, announced a four-year strategic partnership to find biomarkers linked with clinical response in up to five of Gilead's pipeline drugs in inflammation, fibrosis, and other diseases.
• In 2020, BiomX and Boehringer Ingelheim teamed to use the microbiome-based biomarker discovery platform to find biomarkers linked with patient characteristics in IBD potentially.

DETAILED SEGMENTATION OF THE GLOBAL HUMAN MICROBIOME MARKET INCLUDED IN THIS REPORT

This research report on the global human microbiome market has been segmented and sub-segmented into the following categories.

By Disease

• Obesity
• Diabetes
• Autoimmune Disorders
• Cancer
• Mental Disorders
• Infectious disease

By Product

• Probiotic
• Foods
• Medical Foods
• Diagnostic Device
• Drugs
• Supplements

By Application

• Therapeutics
• Diagnostics

By Region

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East and Africa